Eupraxia reports Phase 1b/2a RESOLVE data showing EP-104GI cuts moderate-to-severe odynophagia in EoE patients to 25% at 52 weeks

• Eupraxia Pharmaceuticals released new symptom-response data from its ongoing Phase 1b/2a RESOLVE trial of EP-104GI in eosinophilic esophagitis.
• The analysis showed sustained improvements in painful swallowing and difficulty swallowing, with more patients shifting to milder or no symptoms.
• Safety remained supportive, with no treatment-emergent or procedure-related serious adverse events reported across more than 130 treated patients.
• A key interim readout from the Phase 2b placebo-controlled portion of RESOLVE is expected in Q4.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Eupraxia Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001171843-26-005479), on August 13, 2026, and is solely responsible for the information contained therein.